MB07811
- Generic Name
- MB07811
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- -
- CAS Number
- -
- Unique Ingredient Identifier
- -
- Background
MB07811 is the first of a novel class of product candidates discovered by Metabasis designed to lower serum cholesterol and triglycerides. MB07811, a small molecule that is administered orally, has been extensively studied preclinically and is currently undergoing clinical testing. MB07811 combines a novel thyroid hormone receptor agonist with the Company's ...
- Indication
Investigated for use/treatment in hyperlipidemia.
- Associated Conditions
- -
- Associated Therapies
- -
Study of MB07811 in Subjects With Hypercholesterolemia
- First Posted Date
- 2009-04-09
- Last Posted Date
- 2011-08-12
- Lead Sponsor
- Ligand Pharmaceuticals
- Target Recruit Count
- 80
- Registration Number
- NCT00879112
- Locations
- 🇺🇸
Troy Internal Medicine, Troy, Michigan, United States
🇺🇸Jacksonville Center for Clinical Research, Jacksonville, Florida, United States
🇺🇸University Clinical Research, Pembroke Pines, Florida, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath